<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="editorial"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Anesth Analg</journal-id><journal-id journal-id-type="iso-abbrev">Anesth. Analg</journal-id><journal-id journal-id-type="publisher-id">ANE</journal-id><journal-title-group><journal-title>Anesthesia and Analgesia</journal-title></journal-title-group><issn pub-type="ppub">0003-2999</issn><issn pub-type="epub">1526-7598</issn><publisher><publisher-name>Lippincott Williams &#x00026; Wilkin</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7386673</article-id><article-id pub-id-type="art-access-id">00004</article-id><article-id pub-id-type="doi">10.1213/ANE.0000000000005140</article-id><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>Human Leukocyte Antigen-DR Deficiency and Immunosuppression-Related End-Organ Failure in Severe Acute Respiratory Syndrome Coronavirus 2 Infection</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Zmijewski</surname><given-names>Jaroslaw W.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff1">*</xref></contrib><contrib contrib-type="author"><name><surname>Pittet</surname><given-names>Jean-Francois</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2">&#x02020;</xref></contrib><aff id="aff1">From the Departments of <label>*</label>Medicine</aff><aff id="aff2"><label>&#x02020;</label>Anesthesiology and Perioperative Medicine, University of Alabama at Birmingham, Birmingham, Alabama.</aff></contrib-group><author-notes><corresp id="c1">Address correspondence to Jaroslaw W. Zmijewski, PhD, Pulmonary, Allergy &#x00026; Critical Care Medicine, University of Alabama at Birmingham, School of Medicine 901 19th St S, BMRII 406, Birmingham, AL 35294. Address e-mail to <email xlink:href="zmijewsk@uab.edu">zmijewsk@uab.edu</email>.</corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>7</month><year>2020</year></pub-date><pub-date pub-type="ppub"><day>27</day><month>7</month><year>2020</year></pub-date><elocation-id>10.1213/ANE.0000000000005140</elocation-id><history><date date-type="accepted"><day>17</day><month>7</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 International Anesthesia Research Society</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.</license-p></license></permissions><self-uri xlink:href="ane-publish-ahead-of-print-10.1213.ane.0000000000005140.pdf"/></article-meta></front><body><p>Despite remarkable progress in understanding the immune response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), optimal management of immune function during severe viral infections remains a major issue among critically ill patients. In this issue of <italic>Anesthesia &#x00026; Analgesia</italic>, a clinical study by Spinetti et al<sup><xref rid="R1" ref-type="bibr">1</xref></sup> revealed serious concerns about the development of immunosuppression among coronavirusdisease2019 (COVID-19) patients requiring hospitalization in an intensive care unit (ICU). A significant number of patients appeared to develop immune dysfunction, as evidenced by reduced amounts of monocytic human leukocyte antigen-DR (mHLA-DR). A similar observation has been reported in patients who survive severe sepsis or trauma, but later develop life-threatening immunosuppression.<sup><xref rid="R2" ref-type="bibr">2</xref>&#x02013;<xref rid="R4" ref-type="bibr">4</xref></sup></p><p>HLA-DR is a class IIhuman leukocyte antigen (HLA) expressed on the cell surface of antigen-presenting cells, including monocytes, differentiated macrophages and dendritic cells, as well as B cells. Since the first description of role of HLA-DR in immunosuppression,<sup><xref rid="R5" ref-type="bibr">5</xref></sup> HLA-DR expression on monocytes has been subsequently proven to be a reliable marker for evaluating immune dysfunction and risk of secondary bacterial infections in sepsis and trauma patients.<sup><xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R6" ref-type="bibr">6</xref>&#x02013;<xref rid="R8" ref-type="bibr">8</xref></sup> Thus, reduced amounts of HLA-DR can also place COVID-19 patients at high risk of secondary and severe bacterial nosocomial infections. This observation is consistent with a clinical report of secondary bacterial infections and end-organ injury among COVID-19 patients requiring ICU care.<sup><xref rid="R9" ref-type="bibr">9</xref></sup></p><p>A recent examination of HLA variations among the world population revealed a significant impact of HLAs on the cellular immune response, in particular, on peptides from coronavirus-infected patients. HLA-B*15:03 exhibited the greatest capacity to present highly conserved, shared SARS-CoV2 peptides to immune cells.<sup><xref rid="R10" ref-type="bibr">10</xref></sup> Subsequent studies have recently confirmed that immune dysregulation in COVID-19 patients with respiratory failure is associated with a significant downregulation of monocyte HLA-DR.<sup><xref rid="R11" ref-type="bibr">11</xref></sup></p><p>An excessive inflammatory response to SARS-CoV2 has been thought to be the major cause of disease severity and death among patients with COVID-19 in the ICU setting.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> In this context, exaggerated neutrophil and macrophage/monocyte proinflammatory activation may trigger development of immune dysfunction, including immune tolerance (defective response to bacterial products, eg, lipopolysaccharide) and reduced host immune capacity against bacterial infections.<sup><xref rid="R13" ref-type="bibr">13</xref>&#x02013;<xref rid="R15" ref-type="bibr">15</xref></sup> Such inflammatory mechanisms can be relevant in the development of immunosuppression in sepsis survivors, consistent with reduced HLA-DR expression on monocytes after an initial activation of immune cells during sepsis syndrome.</p><p>However, recent studies have indicated that patients with SARS-CoV2 infection admitted to an ICU have significantly lower levels of cytokine production, as compared to sepsis-related ARDS.<sup><xref rid="R16" ref-type="bibr">16</xref></sup> Therefore, such findings dispute a relevance of &#x0201c;cytokine storm&#x0201d; in COVID-19&#x02013;related development of severe respiratory dysfunction and failure. These findings also indicate that more research is needed to better define the pathophysiology of SARS-CoV2and associated immunosuppression.</p><p>Notably, the mechanisms underlying the downregulation of HLA-DR in sepsis and trauma are also not well understood. Nevertheless, once HLA-DR is decreased or deficient, this event upregulates surface expression of the negative co-stimulatory molecules programmed death 1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), B- and T-lymphocyte attenuator (BTLA), and their corresponding ligands, such as PD-1 ligand (PD-L1). These actions can compromise innate and adaptive immune systems, including cluster of differentiation (CD)8- and anergic CD4-positive T cells, and inducing T cell apoptosis. It could be speculated if these are relevant immunosuppressive mechanisms associated with severe SARS-CoV2 infections (Figure). Furthermore, although HLA-DR is diminished in monocytes during sepsis and viral infection, many other events can trigger immunosuppression, including T cell senescence, exhaustion, and skewing toward the TH17 phenotype.<sup><xref rid="R17" ref-type="bibr">17</xref></sup></p><fig id="F1" orientation="portrait" position="float"><label>Figure.</label><caption><p>Reduced levels of HLA-DR are associated with the development of immunosuppression, high risk of secondary bacterial infections, and end-organ failure in intensive care unit patients with SARS-CoV2. ARDS indicates xxx; HLA-DR, human leukocyte antigen-DR; M&#x00424;, macrophages; PD-L1, programmed death 1 ligand; SARS-CoV2, severe acute respiratory syndrome coronavirus 2.</p></caption><graphic xlink:href="ane-publish-ahead-of-print-10.1213.ane.0000000000005140-g001"/></fig><p>The development of immunosuppression is certainly linked to host&#x02019;s maladaptive response to SARS-CoV2, likely related to preexisting conditions like aging, diabetes, and cardiovascular complications.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> Immunosuppression elicited in anticancer treatments and graft transplantations are also significant issues leading to infections, including worse outcomes with SARS-CoV2 infection.</p><p>Several epidemiological studies have shown that aging is disproportionally linked to more cases, increased severity of organ injury, and mortality related to COVID-19.<sup><xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R20" ref-type="bibr">20</xref></sup> This is a significant issue because aging is characterized by a collective loss of immune responsiveness and paradoxically low-grade chronic inflammation (&#x0201c;inflammaging&#x0201d;).<sup><xref rid="R21" ref-type="bibr">21</xref></sup> Importantly, although CD14<sup>+</sup>CD16<sup>+</sup> monocytes significantly increased with age, but they also displayed reduced HLA-DR surface expression in the elderly.<sup><xref rid="R22" ref-type="bibr">22</xref></sup> It is important to note that a reduced abundance of HLA-DR is likely not a sole biological event becausemany hallmarks of aging are coupled with host&#x02013;coronavirus interactions in direct and indirect ways, including genomic instability, reduced mitochondrial function, epigenetic alterations, telomere attrition, and impaired autophagy.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> In particular, mitochondrial dysfunction and metabolic profile of immune and alveolar epithelial cells play a crucial role in bioenergetic maladaptation in response to viral infections.<sup><xref rid="R23" ref-type="bibr">23</xref></sup> Mitochondrial antiviralsignaling (MAVS) proteins can be released/activated upon viral infection, including SARS-CoV2. MAVS-mediated apoptosis can be suppressed by viral proteins and prevent mitochondrial death or apoptosis to limit virus propagation.<sup><xref rid="R24" ref-type="bibr">24</xref></sup> On the other hand, leukopenia developed in approximately 70% of hospitalized patients with COVID-19, and the mechanism of this cell line death/exhaustion remains to be determined.<sup><xref rid="R25" ref-type="bibr">25</xref></sup></p><p>Diabetes and obesity are leading causes of the morbidity and mortality associated with viral infection&#x02013;related cardiovascular complications. Type 2 diabetes mellitus (T2DM) is a serious preexisting metabolic syndrome with adverse outcomes in patients with hemagglutinin type 1 and neuraminidase type 1 (influenza strain) (H1N1) influenza and SARS-CoV2 in ICU.<sup><xref rid="R26" ref-type="bibr">26</xref>&#x02013;<xref rid="R29" ref-type="bibr">29</xref></sup> Diabetes-related hyperglycemia is closely linked to thedevelopment of acute ketoacidosis and other metabolic alteration, as well as chronic low-gradeinflammation.<sup><xref rid="R30" ref-type="bibr">30</xref></sup> A possible impact of T2DM on mortality due to viral infections is the abundance of glucose that favors virus replication. Diabetes is also characterized by innate immunity dysfunction, including reduced chemotaxis, phagocytosis, andpathogen killing by monocytes and polymorphonuclear neutrophils.<sup><xref rid="R31" ref-type="bibr">31</xref></sup> Interestingly, it has been suggested that HLA regulates immunoreactive inflammation or infection associated with type 2 diabetes. However, the role of HLA alleles in pathogenesis of T2DM and T1DM, and subsequent complications are less clear, as both positive and negative associations of DR alleles have been observed.<sup><xref rid="R32" ref-type="bibr">32</xref>,<xref rid="R33" ref-type="bibr">33</xref></sup> Such discrepancies are likely because diabetes mellitus is a multifactorial disease. Nevertheless, it would be interesting to determine if a decrease of specific HLA-DR alleles contributes to worst outcome in patients withdiabetesand critically illobese patients with COVID-19.</p><p>While interventions available for sepsis and severe trauma are limited to fluid resuscitation and antibiotics, immunomodulatory mechanisms remain the major targets for thedevelopment of effective therapies. Perhaps, successful completion of a clinical trial for PD-L1 in sepsis could also be tested as a therapy for COVID-19&#x02013;related immunosuppression. Given results obtained by Spinetti et al,<sup><xref rid="R1" ref-type="bibr">1</xref></sup> this seems to be a relevant approach to diminishing morbidity and mortality among ICU patients with COVID-19. Another potential benefit is utilization of HLA-DR variants as a prognostic tool to identify individuals with a higher risk for severe infection and hospitalization due to COVID-19.</p><sec><title>DISCLOSURES</title><p><bold>Name:</bold> Jaroslaw W. Zmijewski, PhD.</p><p><bold>Contribution:</bold> This author helped develop the concept, write the manuscript, and design Figure 1.</p><p><bold>Name:</bold> Jean-Francois Pittet, MD.</p><p><bold>Contribution:</bold> This author helped edit and revise the final version of the manuscript.</p><p><bold>This manuscript was handled by:</bold> Thomas R. Vetter, MD, MPH.</p></sec></body><back><fn-group><title>FOOTNOTES</title><fn fn-type="other"><p><def-list><title>GLOSSARY</title><def-item><term>ARDS</term><def><p>xxx</p></def></def-item><def-item><term>BTLA</term><def><p>B- and T-lymphocyte attenuator</p></def></def-item><def-item><term>CD</term><def><p>cluster of differentiation</p></def></def-item><def-item><term>COVID-19</term><def><p>coronavirus disease 2019</p></def></def-item><def-item><term>CTLA-4</term><def><p>cytotoxic T-lymphocyte antigen 4</p></def></def-item><def-item><term>H1N1</term><def><p>hemagglutinin type 1 and neuraminidase type 1 (influenza strain)</p></def></def-item><def-item><term>HLA</term><def><p>human leukocyte antigen</p></def></def-item><def-item><term>HLA-B*15:03</term><def><p>xxx</p></def></def-item><def-item><term>ICU</term><def><p>intensive care unit</p></def></def-item><def-item><term>M&#x00424;</term><def><p>macrophages</p></def></def-item><def-item><term>MAVS</term><def><p>mitochondrial antiviral signaling</p></def></def-item><def-item><term>mHLA-DR</term><def><p>monocytic human leukocyte antigen-DR</p></def></def-item><def-item><term>PD-1</term><def><p>programmed death 1</p></def></def-item><def-item><term>PD-L1</term><def><p>programmed death 1 ligand</p></def></def-item><def-item><term>SARS-CoV2</term><def><p>severe acute respiratory syndrome coronavirus 2</p></def></def-item><def-item><term>T1DM</term><def><p>type 1 diabetes mellitus</p></def></def-item><def-item><term>T2DM</term><def><p>type 2 diabetes mellitus</p></def></def-item><def-item><term>TH17</term><def><p>xxx</p></def></def-item></def-list>
</p></fn><fn fn-type="financial-disclosure"><p>Funding: This work was supported by grants from US Department of Defense (W81XWH-17-1-0577 [to J.W.Z]) and National Institutes of Health (NIH) (R01 HL139617-01 [to J.W.Z]).</p></fn><fn fn-type="COI-statement"><p>The authors declare no conflicts of interest.</p></fn><fn fn-type="other"><p>Reprints will not be available from the authors.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spinetti</surname><given-names>T</given-names></name><name><surname>Hirzel</surname><given-names>C</given-names></name><name><surname>Fux</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Reduced monocytic HLA-DR expression indicates immunosuppression in critically ill COVID-19 patients.</article-title>
<source>Anesth Analg</source>. <year>2020</year>.</mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venet</surname><given-names>F</given-names></name><name><surname>Tissot</surname><given-names>S</given-names></name><name><surname>Debard</surname><given-names>AL</given-names></name><etal/></person-group>
<article-title>Decreased monocyte human leukocyte antigen-DR expression after severe burn injury: correlation with severity and secondary septic shock.</article-title>
<source>Crit Care Med</source>. <year>2007</year>;<volume>35</volume>:<fpage>1910</fpage>&#x02013;<lpage>1917</lpage>.<pub-id pub-id-type="pmid">17568330</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfortmueller</surname><given-names>CA</given-names></name><name><surname>Meisel</surname><given-names>C</given-names></name><name><surname>Fux</surname><given-names>M</given-names></name><name><surname>Schefold</surname><given-names>JC</given-names></name></person-group>
<article-title>Assessment of immune organ dysfunction in critical illness: utility of innate immune response markers.</article-title>
<source>Intensive Care Med Exp</source>. <year>2017</year>;<volume>5</volume>:<fpage>49</fpage>.<pub-id pub-id-type="pmid">29063386</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venet</surname><given-names>F</given-names></name><name><surname>Rimmel&#x000e9;</surname><given-names>T</given-names></name><name><surname>Monneret</surname><given-names>G</given-names></name></person-group>
<article-title>Management of sepsis-induced immunosuppression.</article-title>
<source>Crit Care Clin</source>. <year>2018</year>;<volume>34</volume>:<fpage>97</fpage>&#x02013;<lpage>106</lpage>.<pub-id pub-id-type="pmid">29149944</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volk</surname><given-names>HD</given-names></name><name><surname>Thieme</surname><given-names>M</given-names></name><name><surname>Heym</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Alterations in function and phenotype of monocytes from patients with septic disease&#x02014;predictive value and new therapeutic strategies.</article-title>
<source>Behring Inst Mitt</source>. <year>1991</year>:<fpage>208</fpage>&#x02013;<lpage>215</lpage>.<pub-id pub-id-type="pmid">2049040</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boomer</surname><given-names>JS</given-names></name><name><surname>To</surname><given-names>K</given-names></name><name><surname>Chang</surname><given-names>KC</given-names></name><etal/></person-group>
<article-title>Immunosuppression in patients who die of sepsis and multiple organ failure.</article-title>
<source>JAMA</source>. <year>2011</year>;<volume>306</volume>:<fpage>2594</fpage>&#x02013;<lpage>2605</lpage>.<pub-id pub-id-type="pmid">22187279</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venet</surname><given-names>F</given-names></name><name><surname>Demaret</surname><given-names>J</given-names></name><name><surname>Gossez</surname><given-names>M</given-names></name><name><surname>Monneret</surname><given-names>G</given-names></name></person-group>
<article-title>Myeloid cells in sepsis-acquired immunodeficiency.</article-title>
<source>Ann N Y Acad Sci</source>. <year>2020</year>.</mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuang</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name></person-group>
<article-title>Dynamic monitoring of monocyte HLA-DR expression for the diagnosis, prognosis, and prediction of sepsis.</article-title>
<source>Front Biosci (Landmark Ed)</source>. <year>2017</year>;<volume>22</volume>:<fpage>1344</fpage>&#x02013;<lpage>1354</lpage>.<pub-id pub-id-type="pmid">28199206</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Du</surname><given-names>R</given-names></name></person-group>
<article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.</article-title>
<source>Lancet</source>. <year>2020</year>;<volume>395</volume>:<fpage>1054</fpage>&#x02013;<lpage>1062</lpage>.<pub-id pub-id-type="pmid">32171076</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>A</given-names></name><name><surname>David</surname><given-names>JK</given-names></name><name><surname>Maden</surname><given-names>SK</given-names></name><etal/></person-group>
<article-title>Human leukocyte antigen susceptibility map for severe acute respiratory syndrome coronavirus 2.</article-title>
<source>J Virol</source>. <year>2020</year>;<volume>94</volume>:<fpage>e00510</fpage>&#x02013;<lpage>e00520</lpage>.<pub-id pub-id-type="pmid">32303592</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Rovina</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Complex immune dysregulation in COVID-19 patients with severe respiratory failure.</article-title>
<source>Cell Host Microbe</source>. <year>2020</year>;<volume>27</volume>:<fpage>992.e3</fpage>&#x02013;<lpage>1000.e3</lpage>.<pub-id pub-id-type="pmid">32320677</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merad</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>JC</given-names></name></person-group>
<article-title>Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages.</article-title>
<source>Nat Rev Immunol</source>. <year>2020</year>;<volume>20</volume>:<fpage>355</fpage>&#x02013;<lpage>362</lpage>.<pub-id pub-id-type="pmid">32376901</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venet</surname><given-names>F</given-names></name><name><surname>Monneret</surname><given-names>G</given-names></name></person-group>
<article-title>Advances in the understanding and treatment of sepsis-induced immunosuppression.</article-title>
<source>Nat Rev Nephrol</source>. <year>2018</year>;<volume>14</volume>:<fpage>121</fpage>&#x02013;<lpage>137</lpage>.<pub-id pub-id-type="pmid">29225343</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delano</surname><given-names>MJ</given-names></name><name><surname>Ward</surname><given-names>PA</given-names></name></person-group>
<article-title>Sepsis-induced immune dysfunction: can immune therapies reduce mortality?</article-title>
<source>J Clin Invest</source>. <year>2016</year>;<volume>126</volume>:<fpage>23</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">26727230</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sundar</surname><given-names>KM</given-names></name><name><surname>Sires</surname><given-names>M</given-names></name></person-group>
<article-title>Sepsis induced immunosuppression: implications for secondary infections and complications.</article-title>
<source>Indian J Crit Care Med</source>. <year>2013</year>;<volume>17</volume>:<fpage>162</fpage>&#x02013;<lpage>169</lpage>.<pub-id pub-id-type="pmid">24082613</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinha</surname><given-names>P</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name><name><surname>Calfee</surname><given-names>CS</given-names></name></person-group>
<article-title>Is a &#x0201c;Cytokine Storm&#x0201d; relevant to COVID-19?</article-title>
<source>JAMA Intern Med</source>. <year>2020</year>.</mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Biasi</surname><given-names>S</given-names></name><name><surname>Meschiari</surname><given-names>M</given-names></name><name><surname>Gibellini</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia.</article-title>
<source>Nat Commun</source>. <year>2020</year>;<volume>11</volume>:<fpage>3434</fpage>.<pub-id pub-id-type="pmid">32632085</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>A</given-names></name><name><surname>Jit</surname><given-names>M</given-names></name><name><surname>Warren-Gash</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study.</article-title>
<source>Lancet Glob Health</source>. <year>2020</year>.</mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salimi</surname><given-names>S</given-names></name><name><surname>Hamlyn</surname><given-names>JM</given-names></name></person-group>
<article-title>COVID-19 and crosstalk with the hallmarks of aging.</article-title>
<source>J Gerontol A Biol Sci Med Sci</source>. <year>2020</year>.</mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>NG</given-names></name><name><surname>Klepac</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Age-dependent effects in the transmission and control of COVID-19 epidemics.</article-title>
<source>Nat Med</source>. <year>2020</year>.</mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>EL</given-names></name><name><surname>Shaw</surname><given-names>AC</given-names></name><name><surname>Montgomery</surname><given-names>RR</given-names></name></person-group>
<article-title>How inflammation blunts innate immunity in aging.</article-title>
<source>Interdiscip Top Gerontol Geriatr</source>. <year>2020</year>;<volume>43</volume>:<fpage>1</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">32294641</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seidler</surname><given-names>S</given-names></name><name><surname>Zimmermann</surname><given-names>HW</given-names></name><name><surname>Bartneck</surname><given-names>M</given-names></name><name><surname>Trautwein</surname><given-names>C</given-names></name><name><surname>Tacke</surname><given-names>F</given-names></name></person-group>
<article-title>Age-dependent alterations of monocyte subsets and monocyte-related chemokine pathways in healthy adults.</article-title>
<source>BMC Immunol</source>. <year>2010</year>;<volume>11</volume>:<fpage>30</fpage>.<pub-id pub-id-type="pmid">20565954</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>DE</given-names></name><name><surname>Jang</surname><given-names>GM</given-names></name><name><surname>Bouhaddou</surname><given-names>M</given-names></name></person-group>
<article-title>A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.</article-title>
<source>Nature</source>. <year>2020</year>;<volume>583</volume>:<fpage>459</fpage>&#x02013;<lpage>468</lpage>.<pub-id pub-id-type="pmid">32353859</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>Y</given-names></name><name><surname>Moore</surname><given-names>CB</given-names></name><name><surname>Liesman</surname><given-names>RM</given-names></name></person-group>
<article-title>MAVS-mediated apoptosis and its inhibition by viral proteins.</article-title>
<source>PLoS One</source>. <year>2009</year>;<volume>4</volume>:<fpage>e5466</fpage>.<pub-id pub-id-type="pmid">19404494</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name></person-group>
<article-title>Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study.</article-title>
<source>Signal Transduct Target Ther</source>. <year>2020</year>;<volume>5</volume>:<fpage>33</fpage>.<pub-id pub-id-type="pmid">32296069</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>JK</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>MY</given-names></name></person-group>
<article-title>Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS.</article-title>
<source>Diabet Med</source>. <year>2006</year>;<volume>23</volume>:<fpage>623</fpage>&#x02013;<lpage>628</lpage>.<pub-id pub-id-type="pmid">16759303</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoen</surname><given-names>K</given-names></name><name><surname>Horvat</surname><given-names>N</given-names></name><name><surname>Guerreiro</surname><given-names>NFC</given-names></name><name><surname>de Castro</surname><given-names>I</given-names></name><name><surname>de Giassi</surname><given-names>KS</given-names></name></person-group>
<article-title>Spectrum of clinical and radiographic findings in patients with diagnosis of H1N1 and correlation with clinical severity.</article-title>
<source>BMC Infect Dis</source>. <year>2019</year>;<volume>19</volume>:<fpage>964</fpage>.<pub-id pub-id-type="pmid">31718571</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>A</given-names></name><name><surname>Bhowmik</surname><given-names>B</given-names></name><name><surname>do Vale Moreira</surname><given-names>NC</given-names></name></person-group>
<article-title>COVID-19 and diabetes: knowledge in progress.</article-title>
<source>Diabetes Res Clin Pract</source>. <year>2020</year>;<volume>162</volume>:<fpage>108142</fpage>.<pub-id pub-id-type="pmid">32278764</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>Clinical epidemiological analyses of overweight/obesity and abnormal liver function contributing to prolonged hospitalization in patients infected with COVID-19.</article-title>
<source>Int J Obes (Lond)</source>. <year>2020</year>.</mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knapp</surname><given-names>S</given-names></name></person-group>
<article-title>Diabetes and infection: is there a link?&#x02014;a mini-review.</article-title>
<source>Gerontology</source>. <year>2013</year>;<volume>59</volume>:<fpage>99</fpage>&#x02013;<lpage>104</lpage>.<pub-id pub-id-type="pmid">23182884</pub-id></mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geerlings</surname><given-names>SE</given-names></name><name><surname>Hoepelman</surname><given-names>AI</given-names></name></person-group>
<article-title>Immune dysfunction in patients with diabetes mellitus (DM).</article-title>
<source>FEMS Immunol Med Microbiol</source>. <year>1999</year>;<volume>26</volume>:<fpage>259</fpage>&#x02013;<lpage>265</lpage>.<pub-id pub-id-type="pmid">10575137</pub-id></mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marzban</surname><given-names>A</given-names></name><name><surname>Kiani</surname><given-names>J</given-names></name><name><surname>Hajilooi</surname><given-names>M</given-names></name><name><surname>Rezaei</surname><given-names>H</given-names></name><name><surname>Kahramfar</surname><given-names>Z</given-names></name><name><surname>Solgi</surname><given-names>G</given-names></name></person-group>
<article-title>HLA class II alleles and risk for peripheral neuropathy in type 2 diabetes patients.</article-title>
<source>Neural Regen Res</source>. <year>2016</year>;<volume>11</volume>:<fpage>1839</fpage>&#x02013;<lpage>1844</lpage>.<pub-id pub-id-type="pmid">28123430</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nomura</surname><given-names>S</given-names></name><name><surname>Shouzu</surname><given-names>A</given-names></name><name><surname>Omoto</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Genetic analysis of HLA, NA and HPA typing in type 2 diabetes and ASO.</article-title>
<source>Int J Immunogenet</source>. <year>2006</year>;<volume>33</volume>:<fpage>117</fpage>&#x02013;<lpage>122</lpage>.<pub-id pub-id-type="pmid">16611256</pub-id></mixed-citation></ref></ref-list></back></article>